USPTO 2015–2025 USPTO PatentsView US Corporation

Neuropace, Inc.

USPTO PatentsView assignee record - 111 granted patents across 17 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

111

Total patents granted

CPC technology areas

15.4

Avg claims per patent

-52%

5-year filing velocity

The verdict

Neuropace holds 111 US patents across 17 technology areas, rank #3,354 of 50,000 tracked assignees.

#3,354
of 50,000 US assignees by volume: Top 24%
by Innovation Score (45.2/100): 15.4
avg claims per patent: -52%
filing velocity, last 5 yrs

Portfolio overview

Neuropace, Inc. has been granted 111 US utility patents between 2015 and 2025, placing Neuropace, Inc. at rank #3,354 across all assignees tracked by PlainPatent. This portfolio spans 17 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.4 claims per patent with primary concentration in A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY). As a US Corporation, Neuropace, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Neuropace sits between Kulicke And Soffa Industries, Inc. (111 patents, rank #3,350) and Sagemcom Energy & Telecom SAS (111 patents, rank #3,358) - the closest US assignees by grant volume. The composite Innovation Score of 45.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 36 grants, compared with 75 in the 2015–2019 window, a -52% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Neuropace, Inc.'s 15.4 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 17 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Neuropace, Inc. against peers pursuing similar technology classes.

Kulicke and Soffa…

111
Macneil IP

111
MUSC Foundation f…

111
Millerknoll

111
PTC Therapeutics

111
ROM

111
S V V Technology…

111
Sagemcom Energy &…

111
Neuropace ◀

111

What this shows Neuropace holds 111 patents at rank #3,354, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Neuropace

By rank, the assignees closest to #3,354 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Neuropace's primary technology class.

Neuropace's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

45 Top 24% higher than 76% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Neuropace, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	18	16.2%
2016	23	20.7%
2017	13	11.7%
2018	7	6.3%
2019	14	12.6%
2020	6	5.4%
2021	5	4.5%
2022	5	4.5%
2023	9	8.1%
2024	5	4.5%
2025	6	5.4%

Which technologies does Neuropace, Inc. patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY 96

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 67

A61F - FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS 18

G16H - HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA 15

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 8

G06F - ELECTRIC DIGITAL DATA PROCESSING 7

G06N - COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS 6

H04W - WIRELESS COMMUNICATION NETWORKS 4

H01R - ELECTRICALLY-CONDUCTIVE CONNECTIONS; STRUCTURAL ASSOCIATIONS OF A PLURALITY OF MUTUALLY-INSULATED ELECTRICAL CONNECTING ELEMENTS; COUPLING DEVICES; CURRENT COLLECTORS 3

H01Q - ANTENNAS, i.e. RADIO AERIALS 3

H04Q - SELECTING 2

G06V - IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING 2

H04L - TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION 2

H05K - PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS 1

A63F - CARD, BOARD, OR ROULETTE GAMES; INDOOR GAMES USING SMALL MOVING PLAYING BODIES; VIDEO GAMES; GAMES NOT OTHERWISE PROVIDED FOR 1

Top 15 of 17 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Focused

Claim Depth Standard

Velocity Declining

Where it ranks

Overall rank by patents

#3,354

Across all tracked assignees

Innovation Score

45.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Neuropace, Inc. hold?

Neuropace, Inc. holds 111 US granted patents filed between 2015 and 2025, spanning 17 technology areas.

What is Neuropace, Inc.'s Innovation Score?

Neuropace, Inc. has an Innovation Score of 45.2 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Neuropace, Inc. focus on?

Neuropace, Inc.'s top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY) with 96 patents. The company has filed patents in 17 CPC subclasses total.

Is Neuropace, Inc.'s patent filing rate increasing or decreasing?

Neuropace, Inc.'s recent filing velocity is -52% compared to the prior five-year period. Filing activity has slowed relative to earlier years.

What does claim depth mean for Neuropace, Inc.'s patents?

Neuropace, Inc.'s patents average 15.4 claims each. This falls within the standard range, providing solid legal coverage.

How is the Neuropace, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Neuropace's 111 grants land it in the top 24% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Neuropace ranks #3,354 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61N - see who else leads that technology area. A61N leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.